OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
September 03, 2014
Experts from PPD provided commentary on the evolving role of contract services in analytical services.
Franco Negron, vice president of North America operations and integration at Patheon Inc., provided commentary on the evolving role of contract services in solid/semi-solid dosage development and manufacturing.
Mark Rogers, senior vice president at SGS Life Science Services, provided commentary on the evolving role of contract services in analytical services.
Experts at Dr. Reddy's CPS provided commentary on the evolving role of contract services in biologics drug development and manufacturing, and solid/semi-solid development manufacturing.
Peter Soelkner, general manager at Vetter Pharma International GmbH, provided commentary on the evolving role of contract services in parenteral drug development and manufacturing.
Andrew Strong, president and CEO of Kalon Kalon Biotherapeutics, provided commentary on the evolving role of contract services in biologics drug development and manufacturing.
Ron Connolly, vice president of commercial operations at Frontage Labs, provided commentary on the role of contract services in analytical services.
September 02, 2014
Experts at Xcelience provided commentary on the evolving role of contract services in analytical services and solid/semi-solid development manufacturing.
The quality-by-design principles used to control process variability are equally important to measurement systems because process variability includes contributions from measurement system variability. The authors use real-life examples from drug development projects to outline how an understanding of chromatographic measurement system variability might be achieved.
Experts from Baxter BioPharma Solutions provided the following commentary on trends in bio/pharmaceutical development outsourcing.